AstraZeneca tests booster vaccine against COVID-19 variant
AstraZeneca and the University of Oxford began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.
Andrew Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford said, “testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the coronavirus pandemic, should their use be needed.”
The booster vaccine’s trial will involve around 2,250 participants from Britain, South Africa, Brazil and Poland.
They include people who have been fully vaccinated with two doses of the original Oxford-AstraZeneca vaccine or an mRNA vaccine such as Pfizer as well as those who have not gotten the vaccine at all.
The new vaccine, known as AZD2816, has been designed using the same base as the main AstraZeneca shot but with minor genetic alterations to the spike protein based on the Beta variant.
Britain has had a successful vaccine rollout programme, but experts do not know how long protection lasts.
Maheshi Ramasamy, Principal Investigator at the Oxford Vaccine Group said, “This study will provide vital evidence on whether further doses including tweaks against new virus variants may be needed in the future.”
Current vaccines are believed to be less effective against the Beta variant, although it is the Delta variant, which emerged in India, that is currently causing most concern.
Although the main vaccines are believed to be highly effective at preventing serious illness, the Delta variant’s transmissible nature is leading to a spike in cases in some countries, including Britain.
Initial data from the trial is expected later this year.
READ ALSO: Britain in talks with AstraZeneca to combat ‘beta’ COVID-19 variant
Kamila/Punch
